Abstract:Background and objectives PEG-rhGH (Jintrolong®, 0.2 mg/kg/week) is approved in China for the treatment of growth hormone deficiency (GHD) in children. Although 0.2 mg/kg/2 weeks PEG-rhGH failed the non-inferiority threshold of 20% compared with 0.2 mg/kg/week PEG-rhGH, it notably increases serum IGF-1 levels and height velocity in a phase IV trial. In the absence of investigation on the relationship between pharmacokinetics and pharmacodynamics, this analysis aimed to build a population pharmacokinetic/pharmacodynamic (PopPK/PD) model to characterize the relationship between serum PEG-rhGH concentration and serum insulin-like growth factor-1 (IGF-1) levels after subcutaneously administration of PEG-rhGH and to explore the possibility of flexible dosing schemes and improve the clinical monitor practice of IGF-1 levels. Methods A total of 41 subjects were included for the PopPK analysis, consisting of 30 healthy adults (single dose of 0.1–0.4 mg/kg) and 11 GHD children (multiple doses of 0.2 mg/kg/2 weeks for 26 consecutive weeks). Only GHD children were included for the PopPK/PD analysis. The time courses of serum PEG-rhGH concentrations in healthy adults and GHD children and those of serum IGF-1 levels stimulated by serum PEG-rhGH were well developed with non-linear mixed-effects modeling. Results Serum PEG-rhGH pharmacokinetics after subcutaneous administration were adequately described by a one-compartment model with a zero-order input into the absorption compartment followed by first-order absorption dictating absorption into the central compartment, with a dual elimination process consisting of a capacity limited process and a non-capacity limited process. Body weight was a significant covariate. The drug effects on IGF-1 levels were adequately described by a turnover model with saturable effect relationship. IGF-1 responses at the various dosing scheme scenarios were simulated, and illustrated that dosing schemes with intervals longer than the approved one week could be promising, which may provide comparable peaks and average IGF-1 levels and IGF-1 SDS to dosing schemes that have been clinically proven to be tolerated and effective. An accurate prediction of the time course of the effect of various dosing schemes may assist the clinical monitoring practice. Conclusions This pharmacokinetic/pharmacodynamic analysis suggested that longer intervals or higher dosing strengths (e.g., 0.3 mg/kg/10 days) in children with GHD are promising compared with the approved dosing scheme (0.2 mg/kg/week). Our simulation may assist the clinical monitoring of the PEG-rhGH therapy.

Peg-Rhgh Therapy for Small for Gestational Age Rats and Effects on Their Metabolic Parameters

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age.

The Effect of Polyethylene Glycol Recombinant Human Growth Hormone on Growth and Glucose Metabolism in Hypophysectomized Rats.

Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Beta/Beta-Catenin Signaling In Neonatal Rats

Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Β/β-Catenin Signaling in Neonatal Rats.

Metabolomic Differential Compounds Reflecting the Clinical Efficacy of Polyethylene Glycol Recombinant Human Growth Hormone in the Treatment of Childhood Growth Hormone Deficiency

Effects of PEG-rhGH on organ function of hypophysectomized rats

Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study

Effect of pegylation recombinant human growth hormone on secretion function of pancreas islet in hypophysectomized rats and its mechanism

A Phase 2 Study of PEGylated Recombinant Human Growth Hormone for 52 Weeks in Short Children Born Small for Gestational Age in China

Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study

The Impact of Pegylated Recombinant Human Growth Hormone Replacement Therapy on Glucose and Lipid Metabolism in Children with Growth Hormone Deficiency.

Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study

Metabolic and Growth Outcome of Two-year Growth Hormone Treatment in Children Born Small for Gestational Age: A Retrospective Study

Efficacy of Recombinant Human Growth Hormone Treatment in Children Born Small for Gestational Age with Syndromic and Non-Syndromic Short Stature

Long-acting PEGylated Growth Hormone in Children with Idiopathic Short Stature

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Polyethylene Glycol Recombinant Human Growth Hormone in Chinese Prepubertal Slow-Growing Short Children: Doses Reported in a Multicenter Real-World Study

Population Pharmacokinetic/Pharmacodynamic Analysis of PEG-rhGH Enhances Confidence in Exploring Dosing Schemes with Longer Intervals

Auxological and metabolic effects of long-term treatment with recombinant growth hormone in children born small for gestational age: a retrospective study

Changes of somatotropin axis in catch-up growth rats born small for gestational age